Drug
Naloxegol clinical trials
Also written NKTR-118.
- studies test it
- 34
- open now
- 0
- in phase 3
- 9
- first study started
- 2007
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2011 (11); 1 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 11 |
| 2012 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 7 |
| 2018 | 2 |
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 7
- Phase 3
- 9
- Phase 4
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 15
AstraZeneca (18) · Massachusetts General Hospital (2) · Temple University (2) · CMC Ambroise Paré (1) · University of Missouri-Columbia (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · The Cleveland Clinic (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Methylnaltrexone (1) · Codeine (1) · Polyethylene glycol 3350 (1) · Polyethylene Glycols (1)
Studies
Open first, then newest update. How each study uses naloxegol is read from its arms, and is right about nine times in ten.
Testing it · 34
- Evaluation of Naloxegol in the Prevention of POI After CystectomyWithdrawnPhase 2Institut Paoli-CalmettesNCT04219046Written as Naloxégol oxalate
- The NIPA Study Naloxegol Administration to Prevent Opioids Induced Gastrointestinal Motility Disturbance in Brain Injured PAtientsSuspendedPhase 3University Hospital, BrestNCT05008926Written as Naloxegol
- Effect of Naloxegol on Postoperative Ileus in Patients Undergoing Cardiac SurgeryCompletedPhase 3CMC Ambroise ParéNCT04433390Written as Naloxegol
- Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerTerminatedPhase 2Alliance for Clinical Trials in OncologyNCT03087708Written as Naloxegol
- Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced ConstipationCompletedPhase 4University of Missouri-ColumbiaNCT03523520Written as Naloxegol 25 MG Oral Tablet
- Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC PatientsCompletedPhase 1Kyowa Kirin Pharmaceutical Development LtdNCT02099591Written as Naloxegol
- Ancillary Effects of Oral Naloxegol (Movantik)CompletedPhase 4The Cleveland ClinicNCT03235739Written as Naloxegol 25 MG
- Colonic Motor Patterns in Healthy VolunteersCompletedPhase 4Universitaire Ziekenhuizen KU LeuvenNCT05770960Written as Naloxegol
- Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered OpioidsTerminatedPhase 4Tufts Medical CenterNCT02977286Written as Naloxegol Oral Tablet
- Naloxegol and Opioid-induced ConstipationStatus unknownPhase 2/3TriHealth Inc.NCT03316859Written as Naloxegol 25 MG
- The Effect of Naloxegol on Refractory Constipation in the Intensive Care UnitWithdrawnPhase 3Massachusetts General HospitalNCT02705378Written as naloxegol
- Naloxegol for Opioid-Related GastroparesisWithdrawnPhase 2Temple UniversityNCT03036891Written as Naloxegol 25 MG Oral Tablet [Movantik]
- Naloxegol in Cancer Opioid-Induced ConstipationTerminatedPhase 2Joseph MaNCT02745353Written as naloxegol
- Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery PatientsTerminatedPhase 4Massachusetts General HospitalNCT02946580Written as MOVANTIK™ (naloxegol)
- Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)TerminatedPhase 4Hospice of Henderson County, Inc.NCT02839889Written as Naloxegol
- Movantik for Opioid-Related Esophageal DisordersTerminatedPhase 2Temple UniversityNCT02998606Written as Naloxegol
- To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced ConstipationCompletedPhase 4AstraZenecaNCT03060512Written as Movantik
- A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and SolutionCompletedPhase 1AstraZenecaNCT02446171Written as Naloxegol 25 mg tablet, crushed, suspended in water, given orally
- A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced ConstipationCompletedPhase 3AstraZenecaNCT01395524Written as NKTR-118
- A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)CompletedPhase 2AstraZenecaNCT00600119Written as NKTR-118
Codes
What other systems call naloxegol · ClinicalTrials.gg INT000023
- MeSH (NLM) C000589308naloxegolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 44T7335BKENALOXEGOLConfirmed FDA, NLM, Wikidata
- RxNorm 1551777Confirmed FDA, Wikidata
- Wikidata Q15708351naloxegolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97506NaloxegolOne source FDA
- DrugBank DB09049One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589308 | naloxegol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 44T7335BKE | NALOXEGOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1551777 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708351 | naloxegol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97506 | Naloxegol | One source FDA |
| DrugBank | DB09049 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.